Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

ASTELLAS AT ASH ANNUAL MEETING 2020

ASTELLAS AT ASH ANNUAL MEETING 2020

Learn more about Astellas’ activities at the 2020 American Society of Hematology (ASH) Annual Meeting

ASTELLAS IS COMMITTED TO COMMUNITY SUPPORT

ASTELLAS IS COMMITTED TO COMMUNITY SUPPORT

We are dedicated to supporting local and global communities as part of our COVID-19 response

Astellas a Top Ten Company for Working Mothers

Astellas ranks in Top 10 of Working Mother Magazine’s Best Companies List

We are committed to creating a diverse and inclusive workplace that enables success for all employees

revised newest covid

UPDATES AND INFORMATION

Find out how we're responding to our patients, our employees and our community

1

2

3

4

News

Latest

News / Media

Oct 30, 2020

Astellas Completes Acquisition of iota Biosciences

News / Media

Oct 15, 2020

Astellas to Acquire iota Biosciences

News / Media

Sep 23, 2020

Astellas Collaborates with Two Research Centers at the University of Tokyo

News / Therapeutic Area News

Nov 16, 2020

Astellas to Present New Data on Gilteritinib in FLT3 Mutation-Positive Acute Myeloid Leukemia at the 2020 American Society of Hematology Annual Meeting

News / Therapeutic Area News

Nov 06, 2020

XTANDI® (enzalutamide soft capsules) Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

News / Corporate

Oct 28, 2020

Astellas Receives U.S. FDA Fast Track Designation for ASP5354, an Investigational Near-Infrared Fluorescence Imaging Agent